24
19
1
49
2
2
2c
1b
1d
18
31
46
1d
2 29
1d
25
Katalin Kariko, PhD
78
46
Adjunct Professor of Neurosurgery
7
63
Department: Neurosurgery
4
1
b
1d
46
Contact information
53
4
3
3
1d
53
Perelman Center for Advanced Medicine
22 Department of Neurosurgery
1f 3400 Civic Center Blvd.
3a 15th Floor, South Tower
Philadelphia, PA 19104
26
22 Department of Neurosurgery
1f 3400 Civic Center Blvd.
3a 15th Floor, South Tower
Philadelphia, PA 19104
2e
Office: 215.662.3487
30
81
30
Email:
kariko@upenn.edu
12
kariko@upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
7b Search PubMed for articles
d
4
b
1f
7b Search PubMed for articles
d
13
Education:
21 7 BS 14 (Biology) c
43 József Attila University, Szeged, Hungary, 1978.
21 8 PHD 19 (Biochemistry) c
43 József Attila University, Szeged, Hungary, 1982.
c
3
3
21
21 7 BS 14 (Biology) c
43 József Attila University, Szeged, Hungary, 1978.
21 8 PHD 19 (Biochemistry) c
43 József Attila University, Szeged, Hungary, 1982.
c
1f
Post-Graduate Training
24 7d Postdoctoral Fellow, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary, 1982-1985.
24 72 Postdoctoral Fellow, Department of Biochemistry, Temple University, Philadelphia, PA, 1985-1988.
24 8e Postdoctoral Fellow, Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, 1988-1989.
c
3
3
8b
Permanent link24 7d Postdoctoral Fellow, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary, 1982-1985.
24 72 Postdoctoral Fellow, Department of Biochemistry, Temple University, Philadelphia, PA, 1985-1988.
24 8e Postdoctoral Fellow, Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, 1988-1989.
c
2 29
21
1e
1d
24
5e
26 29
27
Description of Research Expertise
35c Dr. Katalin Karikó’s research has for decades focused on RNA-mediated mechanisms, with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered (with Penn Medicine colleague Drew Weissman) that nucleoside modifications suppress the immunogenicity of RNA, which has widened the therapeutic potential of mRNA in treating diseases. This led to the development of the two most effective vaccines for COVID-19, the BioNTech/Pfizer and Moderna vaccines, and holds vast promise for future treatments of many other diseases. Dr. Karikó was recently honored with the Breakthrough Prize in Life Sciences, the Princess of Asturias Award, and the Vilcek Prize for Excellence in Biotechnology. She continues to work on new therapeutic applications of mRNA therapy.26 29
23
2c3 Hotz, C, Wagenaar, TR, Gieseke, F, Bangari, DS, Callahan, M, Cao, H, Diekmann, J, Diken, M, Grunwitz, C, Hebert, A, Hsu, K, Bernardo, M, Karikó, K, Kreiter, S, Kuhn, AN, Levit, M, Malkova, N, Masciari, S, Pollard, J, Qu, H, Ryan, S, Selmi, A, Schlereth, J, Singh, K, Sun, F, Tillmann, B, Tolstykh, T, Weber, W, Wicke, L, Witzel, S, Yu, Q, Zhang, YA, Zheng, G, Lager, J, Nabel, GJ, Sahin, U, and Wiederschain, D: Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine 13(610): eabc7804, Sep 2021 Notes: [Epub Ahead of Print]
28e Sahin, U, Muik, A, Derhovanessian, E, Vogler, I, Kranz, LM, Vormehr, M, Baum, A, Pascal, K, Quandt, J, Maurus, D, Brachtendorf, S, Lorks, V, Sikorski, J, Hilker, R, Becker, D, Eller, AK, Grutzner, J, Boesler, C, Rosenbaum, C, Kuhnle, MC, Luxemburger, U, Kemmer-Bruck, A, Langer, D, Bexon, M, Bolte, S, Karikó, K, Palanche, T, Fischer, B, Schultz, A, Shi, PY, Fontes-Garfias, C, Perez, JL, Swanson, KA, Loschko, J, Scully, IL, Cutler, M, Kalina, W, Kyratsous, CA, Cooper, D, Dormitzer, PR, Jansen, KU, and Tureci, O.: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2 32 586(7830): 594-599, Oct 2020.
155 Karikó, K., Muramatsu, H., Welsh, FA., Ludwig, J., Kato, H., Akira, S., Weissman, D.: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy 16: 1833-1840, 2008.
112 Karikó K, Buckstein M, Ni H, Weissman D.: Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2): 165-75, 2005.
2c
7
1d
1f
Selected Publications
19b Krienke, C, Kolb, L, Diken, E, Streuber, M, Kirchhoff, S, Bukur, T, Akilli-Öztürk, Ö, Kranz, LM, Berger, H, Petschenka, J, Diken, M, Kreiter, S, Yogev, N, Waisman, A, Karikó, K, Türeci, Ö, and Sahin, U : A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371(6525): 145-153, Jan 2021.2c3 Hotz, C, Wagenaar, TR, Gieseke, F, Bangari, DS, Callahan, M, Cao, H, Diekmann, J, Diken, M, Grunwitz, C, Hebert, A, Hsu, K, Bernardo, M, Karikó, K, Kreiter, S, Kuhn, AN, Levit, M, Malkova, N, Masciari, S, Pollard, J, Qu, H, Ryan, S, Selmi, A, Schlereth, J, Singh, K, Sun, F, Tillmann, B, Tolstykh, T, Weber, W, Wicke, L, Witzel, S, Yu, Q, Zhang, YA, Zheng, G, Lager, J, Nabel, GJ, Sahin, U, and Wiederschain, D: Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine 13(610): eabc7804, Sep 2021 Notes: [Epub Ahead of Print]
28e Sahin, U, Muik, A, Derhovanessian, E, Vogler, I, Kranz, LM, Vormehr, M, Baum, A, Pascal, K, Quandt, J, Maurus, D, Brachtendorf, S, Lorks, V, Sikorski, J, Hilker, R, Becker, D, Eller, AK, Grutzner, J, Boesler, C, Rosenbaum, C, Kuhnle, MC, Luxemburger, U, Kemmer-Bruck, A, Langer, D, Bexon, M, Bolte, S, Karikó, K, Palanche, T, Fischer, B, Schultz, A, Shi, PY, Fontes-Garfias, C, Perez, JL, Swanson, KA, Loschko, J, Scully, IL, Cutler, M, Kalina, W, Kyratsous, CA, Cooper, D, Dormitzer, PR, Jansen, KU, and Tureci, O.: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2 32 586(7830): 594-599, Oct 2020.
155 Karikó, K., Muramatsu, H., Welsh, FA., Ludwig, J., Kato, H., Akira, S., Weissman, D.: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy 16: 1833-1840, 2008.
112 Karikó K, Buckstein M, Ni H, Weissman D.: Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2): 165-75, 2005.
2c
44
23
Back to Top
1b
1d
18